

# Eculizumab in Shiga-Toxin producing E. Coli Haemolytic Uraemic Syndrome (ECUSTEC): A Randomised, Double Blind, Placebo-Controlled Trial

Dear Consultant Paediatric Neurologist,

### Re: ECUSTEC Day 60 Central Nervous System Assessment – guidance for Paediatric Neurologists

Thank you for your willingness to be a part of the ECUSTEC trial. The primary outcome measure is a multi-domain clinical severity score that captures the severity of renal and extra-renal events as a consequence of Shiga-Toxin E. Coli Haemolytic Uraemic Syndrome (STEC HUS) (Appendix 1). It is assigned after the Day 60 assessment.

The CNS domain score is shown here:

CNS score (assign the highest score that applies)	
Altered consciousness	
(Agitation or irritability or hallucinations or confusion or excessive drowsiness)	2
Single seizure	4
Two or more seizures 24 hrs apart*	6
Transient focal neurological defect (>24 hrs** but <1 week)	7
Persistent focal neurological defect (present at day 60 and persistent for more	
than 1 week)	10
Persistent global (≥ 2 brain functions - vision/hearing/cognitive/motor/sensory/memory) neurological defect at day 60	15

<sup>\*</sup> Multiple seizures occurring within a 24 hr period considered part of the same event

If any of the following features are present during the acute illness, the research team at the recruiting hospital will arrange CNS assessment as part of the Day 60 assessment:

CNS features during acute illness that indicate the need for the Day 60 CNS assessment
Altered consciousness (Agitation, irritability, hallucinations, confusion, excessive
drowsiness)
Seizure/s
Focal or global neurological defect of any duration

The Day 60 CNS assessment will comprise:

- 1. Structured examination by Consultant Paediatric Neurologist
- 2. Visual assessment by an optometrist and ophthalmologist
- 3. Hearing assessment by an audiologist


<sup>\*\*</sup>Todd's paresis following a seizure should resolve within 24 hrs

4. Neuropsychology assessment (parental completion of the Adaptive Behaviour Assessment System Third Edition (ABAS-3) form) supervised by a neuropsychologist

Worksheets for these assessments are contained within the site file, and an example of each is enclosed with this guidance (Appendix 2). These are designed to capture <u>new</u> features of CNS disease that since the onset of STEC HUS. Any pre-existing abnormalities should not be recorded.

Once the Day 60 CNS assessments are complete, we would be grateful if you would review the data from the worksheets and assign the appropriate CNS score which will be sent to BCTU via the Day 60 Case Report Form (CRF). This will be added to the scores from the other domains to complete the primary outcome measure.

This process is summarised in the diagram below:



Once again, many thanks for your support for the ECUSTEC trial. If you have any questions please do not hesitate to contact:

### **Principal Investigator:**

**BCTU**: Emma Barsoum, Senior Trial Coordinator Tel. 0121 415 9132 or email <a href="mailto:ecustec@trials.bham.ac.uk">ecustec@trials.bham.ac.uk</a>

Chief Investigator: Dr Sally Johnson Tel. 0121 282 4917 or email Sally.Johnson@nuth.nhs.uk

Yours sincerely

Dr Sally Johnson

Chief Investigator ECUSTEC Trial

# **Appendix 1: Clinical Severity Score (primary outcome measure)**

	To 100 and 100	1.
Renal	Lowest eGFR >50	1
	Lowest eGFR 26-50, no oligoanuria*	2
	Lowest eGFR ≤ 25, no oligoanuria*	3
	Oligoanuria* but no dialysis (or renal replacement therapy, RRT) required	4
	Dialysis/RRT <48 hours	5
	Dialysis/RRT 2 days	6
	Dialysis/RRT 3 days	7
	Dialysis/RRT 4 days	8
	Dialysis/RRT 5 days	9
	Dialysis/RRT 6 days	10
	Dialysis/RRT 7 days	11
	Dialysis/RRT 8 days	12
	Dialysis/RRT 9 days	13
	Dialysis/RRT 10 days	14
	Dialysis/RRT 11 days	15
	Dialysis/RRT 12 to 13 days	16
	Dialysis/RRT 14 to 17 days	17
	Dialysis/RRT 18 to 20 days	18
	Dialysis/RRT 21 to 27 days	19
	Dialysis/RRT 28 to 34 days	20
	Dialysis/RRT 35 to 41 days	21
	Dialysis/RRT 42 to 48 days	22
	Dialysis/RRT 49 to 55 days	23
	Dialysis/RRT >55 days	24
CNS	No obvious CNS involvement	0
	Altered consciousness (Agitation, irritability, hallucinations, confusion, excessive drowsiness)	2
	Single seizure	4
	Two or more seizures 24 hrs apart**	6
	Transient focal neurological defect (>24 hrs*** but <1 week)	7
	Persistent focal neurological defect (present at day 60 and persistent for more than 1 week)	10
	Persistent global (≥ 2 brain functions - vision/hearing/cognitive/motor/sensory/memory) neurological defect at day 60	15
Pancreas	No clinical or biochemical evidence pancreatitis	0
	Raised amylase and/or lipase† without clinical symptoms/signs	2
	Hyperglycaemia without insulin requirement	6
	Pancreatitis with sequelae (laparotomy, parenteral nutrition††, insulin required)	8
	Chronic sequelae of pancreatitis at day 60 (parenteral nutrition††, insulin, other)	10
Gastro- intestinal	No abdominal surgery reguired (except related to peritoneal dialysis catheter)	0
	Laparoscopy/laparotomy required for abdominal symptoms	5
	Intestinal perforation AND/OR bowel resection required	8

	Stoma formation	10
Cardiac	No cardiac involvement (normal CVS examination - except hypertension/volume overload)	0
	Cardiac failure confirmed by ECHO††† (impaired systolic ventricular function or chamber enlargement or valve regurgitation)	4
	Cardiac failure confirmed by ECHO with dilated cardiomyopathy	6
	Myocardial infarction (on standard ECG +/- troponin +/- ECHO evidence)	10

<sup>\*</sup>oligoanuria defined as urine output <0.5ml/kg/hr for 12 hours

† lipase measurement not mandatory, however if measured and found to be elevated this would count

†† only if parenteral nutrition is required because of pancreatitis, not for other indications

††† ECHO only mandatory if clinical signs of cardiac failure or myocardial infarction

Within each domain, highest score at any point in first 60 days is recorded and score for each domain is added together to give total clinical severity score.

Abbreviations: eGFR estimated glomerular filtration rate; RRT renal replacement therapy; CNS central nervous system; CVS cardiovascular system; ECHO echocardiogram.

<sup>\*\*</sup> Multiple seizures occurring within a 24 hr period considered part of the same event

<sup>\*\*\*</sup>Todd's paresis following a seizure should resolve within 24 hrs

## Appendix 2: ECUSTEC Day 60 Assessment CNS Worksheets

has this occurred since diagnosis of STEC HUS?

No

Yes

## **ECUSTEC Audiometric Examination Worksheet**

	Hospital name	:			
	Trial number:				
	Date of Birth:				
•		•			patient experienced (
•	•		•		neurologist responsible
rmation on the wo	rksneet as <u>Source</u>	<u>Data</u> from	n which to assi	gn a CNS	S score for the ECUSTEC
Audiometry using	age/ability appro	priate me	thod		
Test used					
	Visual rein	forced a	udiometry		
	Play audio	netry			
	Standard a		•		
	Other	□ s	tate which		
Result Left Ear	Normal		Abnormal		Not possible □
Result Right Ear	Normal		Abnormal		Not possible
Tympanometry					
Tympanometry  Result Left Ear	Normal		Abnormal		Not possible
	Normal Normal		Abnormal Abnormal		Not possible  Not possible
Result Left Ear					•
Result Left Ear					•
Result Left Ear Result Right Ear					•

ECUSTEC CNS Day 60 Assessment Letter to Paediatric Neurologist Version 1.0, 21st November 2017 EudraCT number: 2016-000997-39

Unable to comment □

Supporting comments	

**ECUSTEC Source Data**: this worksheet is to be filed in the ECUSTEC Site File and a copy should be added to the patient medical notes.

# **ECUSTEC Central Nervous System (CNS) Assessment Worksheet**

**Hospital name:** 

	Trial number:							
			<u> </u>					
	Date of Birth:						_	
Please complete t	his worksheet for the	e day 60	assessm	ent v	isit if	the p	atient experi	enced CNS
features during th	e acute disease (STE	C HUS).	Once cor	mplet	ted, th	ne pae	ediatric neuro	ologist
responsible will us	e the information or	n the wo	rksheet	as <u>So</u>	urce [	<u>Data</u> f	rom which to	assign a CNS
score for the ECUS	STEC trial.							
ECUSTEC CNS Asse	essment*							
Level of conscious	ness / alertness							
Result	Normal [		Abnorn	nal			Not possible	· 🗆
Details if abnorma	I							
Cranial nerves								
Result	Normal [	]	Abnorn	nal			Not possible	· 🗆
Details if abnorma	ı					1.	·	
Tone								
Result	Normal [		Abnorn	nal			Not possible	. 🗆
Details if abnorma						<u> </u>	The special section of	
Alamana liki sa sa f	manamant.							
Abnormalities of I	No abnormal		Abnorn	nal		I	Not possible	, п
Nesuit	movements		movem				Not possible	
Details of abnorma			1			<u> </u>		
Abnormalities of l	nalanco/gait							
Abnormalities of I	varance/gail							

Result	Normal balance/gait □	Abnormal balance/gait □	Not possible
Details of abnormal ba		balance/gait 🗅	
Details of ability and	narroc, Bare		
Weakness			
Result	No weakness	Weakness present □	Not possible □
Details of weakness			
Namenath			
Neuropathy	No nouronathu	Cuidones of	Not possible □
Result	No neuropathy □	Evidence of neuropathy	Not possible
Details of neuropathy	<u> </u>	пецгораціу 🗀	
Details of fleuropathy			
New epileptic seizures	(since onset STEC HUS)		
Result	No new seizures	New seizures	Not possible
Details of seizures			
Cummany			
Summary  Does this child have a life	normal neurological exa	mination?	
Yes	No   D		П
	from parental reports ar		<del>_</del>
occurred since onset o		, a. a	
Yes	No 🗆	Unable to comment	
	ı	1	

**ECUSTEC Source Data:** this worksheet is to be filed in the ECUSTEC Site File and a copy should be added to the patient medical notes.

### \*Examination should include the following:

- Level of consciousness / alertness
- Abnormalities of cranial nerves
  - o Single
  - o Multiple
- Abnormalities of tone
  - Hypotonia
    - Axial
    - Post-axial
  - Hypertonia
    - Spastic or dystonic
    - Generalised or focal
    - Arms v legs
    - Trunk v limbs
    - Head lag/drop
- Abnormalities of movement
  - o Tremor
    - Location
    - Rest v Action v Postural
    - Symmetrical
  - Myoclonus
  - Choreoathetosis
    - Location
    - Frequency
- Abnormalities of balance/gait
  - Cerebellar ataxia
    - Upper limb dysmetria
    - Associated conjugate nystagmus
    - Associated tremor
  - Sensory ataxia (peripheral neuropathy)
  - Spastic v waddling v ataxic gait
- Weakness
  - Flaccid v Spastic
  - o Hemiplegia, Monoplegia, Diplegia
  - Proximal v distal
  - Mobility wheelchair; assisted walking; independently mobile (age appropriate)
- Neuropathy
  - Mononeuropathy
  - o Mononeuritis multiplex
- New epileptic seizures (since onset of disease)
  - o Focal v Generalised
  - o Focal semiology; secondary generalisation
  - o Generalised GTCS, absence seizures
  - Frequency of seizure types
  - o Response to medication

# **ECUSTEC Optometric and Ophthalmological Examination Worksheet**

	Hospital name:					
	Trial number:					
	Date of Birth:					
ing the acute disea	worksheet for the dase (STEC HUS). Oncorksheet as <u>Source Da</u>	e compl	eted, the pae	diatric nei	urologist resp	onsible will
Toot wood						
Test used Result	Normal		Abnormal Details		Not possib	le 🗆
Eye alignment Result	Normal		Abnormal Details		Not possib	le 🗆
Eye movement						
Result	Normal		Abnormal Details		Not possib	le 🗆
			Details			
Visual fields						
Test used Result	Normal		Abnormal		Not possib	le 🗆
nesuit	INOTITIAL		Details		ινοι μοσσιο	

ECUSTEC CNS Day 60 Assessment Letter to Paediatric Neurologist Version 1.0, 21st November 2017 EudraCT number: 2016-000997-39

Anterior se	egment						
Result		Normal		Abnormal		Not possible	
				Details			
Posterior s	segment						
Result		Normal		Abnormal		Not possible	
				Details			
Summary							
Does this	child have	a normal visua	l examir	nation?		<u> </u>	
Yes		No		Unable to c	omment		
If no, in y	our opinion	(from parenta	al report	ts and any av	ailable pr	e-morbid recor	rds)
has this o	ccurred sin	ce diagnosis of	f STEC H	US?			
Yes		No		Unable to c	omment		

**ECUSTEC Source Data**: this worksheet is to be filed in the ECUSTEC Site File and a copy should be added to the patient medical notes.

# **ECUSTEC Neuropsychological Assessment Worksheet**

Hospital name:

	Trial number:									
	Date of Birth:									
<u>-</u>										
se complete this v	vorksheet for the d	av 60 a:	ssessme	nt vis	it if t	he p	atient :	experi	enced	CN:
•	se (STEC HUS). Once	•						•		
_	rksheet as Source Da	•		•			_			
				`	-					
Ago	الدندمين ميرد									
Age:yea	arsmonth	าร								
Form used	Parent/Prima	ry Care	giver	P	arent	forr	n			
-orm used	Ages 0-5			A	ges 5	-21				
Scores		Ger	neral Ac	lantiv	re Co	mno	site			
Scores	Standard Sc		neral Ad			mpo		denc	e Inte	val
Scores Pre-morbid?	Standard So		ı	laptiv ercen		mpo		denc	e Inte	·val
Pre-morbid?	Standard S		ı			mpo		denc	e Intei	val
	Standard So		ı			mpo		denc	e Intei	·val
Pre-morbid? Current?	Standard S		ı			mpo		denc	e Intei	val
Pre-morbid?	Standard S		ı			mpo		denc	e Inter	val
Pre-morbid? Current? Summary		core	P	ercer	itile			denc	e Inter	rval
Pre-morbid? Current? Summary Does this child ha	ave an ABAS-3 sco	core re belov	v expec	ercen	itile or age	e?	Confi	denc	e Inter	val
Pre-morbid? Current?  Summary  Does this child have Yes	ave an ABAS-3 scor	core	v expec Unable	ercen	or ago	e?	Confi			rval
Pre-morbid? Current?  Summary  Does this child have Yes	ave an ABAS-3 scor No inion (from compa	core	v expec Unable	ercen	or ago	e?	Confi			val

**ECUSTEC Source Data**: this worksheet is to be filed in the ECUSTEC Site File and a copy should be added to the patient medical notes.